2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161908
    h15-LOX-2 inhibitor 3 1164515-84-7 98%
    h15-LOX-2 inhibitor 3 (Compound 13) is an inhibitor of h15-LOX, with IC50 and Ki values of 25 μM and 15.1 μM, respectively.
    h15-LOX-2 inhibitor 3
  • HY-161935
    6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid 98%
    6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid (Compound 2) exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin enterococci (VRE). 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid interfers with the integrity and function of the bacterial cell membrane, and affects metabolism in MRSA. 6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid exhibits anti-inflammatory and anti-infective efficacy, and promotes angiogenesis in mice.
    6-(12-Tridecene-1-yl)-2,4-Dihydroxy benzoic acid
  • HY-161988
    Antimicrobial agent-34 3055131-42-2 98%
    Antimicrobial agent-34 (compound 4h) is an antibacterial agent (MIC = 1–4 μg/mL), with a clogP value of 9.14. Antimicrobial agent-34 has good plasma stability (HC50 of 131.1 μg/mL) and good membrane selectivity (HC50/MIC is 65.6), with rapid sterilization capability. Antimicrobial agent-34 destroys the integrity of bacterial cell membranes, induces an increase in intracellular reactive oxygen species, and leaks protein and DNA, ultimately leading to bacterial death. Antimicrobial agent-34 demonstrates significant in vivo antibacterial potency in a mouse sepsis model infected with Staphylococcus aureus ATCC43300.
    Antimicrobial agent-34
  • HY-162015
    LTA4H-IN-2 2851480-52-7 98%
    LTA4H-IN-2 (compound (S)-2 ) is an orally active inhibitor of Leukotriene A4 Hydrolase, with an IC50 of <3 nM.
    LTA4H-IN-2
  • HY-162044
    COX-1/2-IN-6 327024-84-0 98%
    COX-1/2-IN-6 (compound 4 h) is a potent dual inhibitor of COX-1 and COX-2 with IC50s of 68 and 91 nM, respectively. COX-1/2-IN-6 can used in study inflammation diseases.
    COX-1/2-IN-6
  • HY-162579
    TLR7 agonist 22 3036114-68-5 98%
    TLR7 agonist 22 (Compound 11a) emerges as a selective TLR7 agonist with an IC50 value of 25.86 μM. TLR7 agonist 22 inhibits the cellular HBsAg secretion and effectively activates TLR7, thereby inducing the secretion of TLR7-regulated cytokines IL-12, TNF-αand IFN-αin human PBMC cells. TLR7 agonist 22 is a promising for research in the field of developing novel immunomodulatory anti-HBV agents.
    TLR7 agonist 22
  • HY-162615
    Antibacterial agent 225 98%
    Antibacterial agent 225 (compound 12a-2) simultaneously exerts excellent bifunctional effects of fungal inhibition and immune activation.
    Antibacterial agent 225
  • HY-162700
    MK2-IN-6 98%
    MK2-IN-6 (Compound 11) is a potent and selective irreversible MK2 inhibitor with an IC50 value of 2.3 nM. MK2-IN-6 inhibits MK2 kinase activity, achieving prolonged MK2 signaling suppression and reducing pathological inflammatory cytokines in macrophages. MK2-IN-6 inhibits the M2-like protumor phenotype of macrophages both in vitro and in vivo, which is proming for research of colorectal cancer.
    MK2-IN-6
  • HY-162761
    COX-1/2-IN-9 98%
    COX-1/2-IN-9 (Compound 3n) is a potent and selective inhibitor of COX-1/2, with IC50 values of 0.031 µM and 0.01 µM, respectively. COX-1/2-IN-9 possesses both antibacterial and anti-inflammatory activities, effectively inhibiting MRSA 1478 (MIC=50 μg/mL) and multidrug-resistant S. lentus (MIC=50 μg/mL). COX-1/2-IN-9 holds significant potential to alleviate MRSA-induced pneumonia in immunocompromised states.
    COX-1/2-IN-9
  • HY-162880
    RIPK1-IN-24 1358585-26-8 98%
    RIPK1-IN-24 is a receptor-interacting protein kinase 1 (RIPK1) inhibitor with an IC50 value of 1.3 μM. RIPK1-IN-24 can be used for research on inflammatory diseases.
    RIPK1-IN-24
  • HY-163030
    LasB-IN-1 98%
    LasB-IN-1 (compound 5f) is a potent and orally active inhibitor of LasB (IC50 = 8.7 μM). LasB-IN-1 effectively attenuates elastase production and biofilm formation by P. aeruginosa while alleviating the inflammatory response through downregulating MAPK and NF-κB pathways. LasB-IN-1 is potential to be a novel anti-infective candidate against drug-resistant infections.
    LasB-IN-1
  • HY-163038
    Sulfamethoxazole-NO hydrate 98%
    Sulfamethoxazole-NO (SMX-NO) hydrate is the reactive metabolite of SMX (HY-B0322). Sulfamethoxazole-NO (SMX-NO) hydrate actis as a typical hapten and is capable of covalently modifying the MHC-peptide complex, can stimulate hapten-reactive T cells.
    Sulfamethoxazole-NO hydrate
  • HY-163103
    (S)-Isomyosmine 67209-94-3 98%
    (S)-Isomyosmine is the S-enantiomer of Isomyosmine (HY-W701069). Isomyosmine is a nitrate reductase inhibitor. Isomyosmine is a nicotine related alkaloid present in solanecea plants containing nicotine. Isomyosmine can be used for research of inflammation and age-related disorders.
    (S)-Isomyosmine
  • HY-163122
    5-Formylsalicylic acid 616-76-2 98%
    5-Formylsalicylic acid (5-F-SA), a hapten, strongly upregulates MR1 expression (MR1 ligand).
    5-Formylsalicylic acid
  • HY-163179
    NLRP3-IN-28 2922814-80-8 98%
    NLRP3-IN-28 (compound N77) is a potent inhibitor of NLRP3. NLRP3-IN-28 inhibits Nigericin (HY-127019)-induced pyroptosis with an EC50 of 0.07μM. NLRP3-IN-28 alleviates the inflammatory reaction in vivo.
    NLRP3-IN-28
  • HY-163551
    BNP peptide/KLH 98%
    The BNP peptide/KLH is an antigen-adjuvant conjugate formed by linking BNP peptide (human brain natriuretic peptide) with keyhole limpet hemocyanin (KLH). By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or damage the major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
    BNP peptide/KLH
  • HY-163648
    Suloxifen 25827-12-7 98%
    Suloxifen is a thioketone compound, which exhibits anti-asthmatic efficacy.
    Suloxifen
  • HY-163843
    Antibacterial agent 234 98%
    Antibacterial agent 234 (6p) is an antibacterial agent. Antibacterial agent 234 (6p) exhibits good activity against Klebsiella pneumoniae with a MIC value of 6.25 µg/mL.
    Antibacterial agent 234
  • HY-163915
    8-(4-(Trifluoromethyl)anilino)quercetin 98%
    8-(4-(Trifluoromethyl)anilino)quercetin is a potent ErmA inhibitor. 8-(4-(Trifluoromethyl)anilino)quercetin has antioxidant and anti-inflammatory activity.
    8-(4-(Trifluoromethyl)anilino)quercetin
  • HY-164012
    Proxicromil 60400-92-2 98%
    Proxicromil is a derivative of chromone. Proxicromil is an orally active anti-asthmatic agent, and exhibits no liver toxicity.
    Proxicromil
Cat. No. Product Name / Synonyms Application Reactivity